stockrow
Friday 6 November 2026
Export BLLN’s income statement to Excel — free account
BillionToOne, Inc.
BLLN Healthcare Diagnostics & Research
BillionToOne, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $305.1 million, up 100.0% from fiscal 2024.
- Revenue
- +47.2%
- EPS
- +164.3%
- Free cash flow
- +9.25%
- Total debt
- +60.6%
Quarter to September 2026, against a year earlier
110.64
1.75
−1.56%
Follow BLLN
Alert me
BillionToOne, Inc. (BLLN) Shares outstanding
BillionToOne, Inc.'s shares outstanding at the end of fiscal 2025 was $21.2M, up 110.6% from $10.1M in fiscal 2024. At the end of the quarter to 30 September 2026 it was $53.7M. BillionToOne, Inc. ranks 26th of 49 Diagnostics & Research companies by shares outstanding.
Shares outstanding, annual
Embed this chart
Annual newest first
| Period | Shares outstanding | Change |
|---|---|---|
| FY2025 | $21.2M | 110.63% |
| FY2024 | $10.1M | 3.04% |
| FY2023 | $9.8M | — |
Quarterly newest first
| Period | Shares outstanding | Change |
|---|---|---|
| Sep 2026 | $53.7M | (1.33%) |
| Jun 2026 | $54.5M | 2.69% |
| Mar 2026 | $53.0M | 149.77% |
| Dec 2025 | $21.2M | 36.34% |
| 4 more quarters | Free account |
Shares outstanding against peers
| Company | Shares outstanding |
|---|---|
| SHC Sotera Health Company compare | $289.2M |
| QGEN QIAGEN N.V. compare | $207.8M |
| ADPT Adaptive Biotechnologies Corporation compare | $186.9M |
| NEO NeoGenomics, Inc. compare | $128.6M |
| VCYT Veracyte, Inc. compare | $82.8M |
| RDNT RadNet, Inc. compare | $78.7M |
| CDNA CareDx, Inc. compare | $55.0M |
| BLLN BillionToOne, Inc. | $53.7M |
| GRAL GRAIL, Inc. compare | $46.8M |
What Shares outstanding is
Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.
Reported line item
More on BLLN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Book value per share
- The full statement